Related Experiment Video
Updated: Mar 4, 2026
09:43
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
3.6K
Decreasing Serum Adropin Levels in Patients With Systemic Lupus Erythematosus: A Case-Control Study.
Mehrzad Hajialilo1, Amir Ghorbanihaghjo2, Kamran Javidi-Aghdam3
1Connective Tissue Diseases Research Center Tabriz University of Medical Sciences Tabriz Iran.
Health Science Reports
|March 3, 2026
Summary
Serum adropin levels are significantly lower in patients with systemic lupus erythematosus (SLE), indicating a potential link to disease activity and cardiovascular risk. Lower adropin may predict hypertension and anti-phospholipid antibodies in SLE patients.
Area of Science:
- Endocrinology
- Immunology
- Cardiovascular Research
Background:
- Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting many women, often co-occurring with obesity.
- Adropin, a peptide hormone, regulates metabolism and possesses anti-inflammatory and immune-modulating properties.
- Understanding adropin's role in SLE is crucial for managing associated metabolic and cardiovascular complications.
Purpose of the Study:
- To investigate serum adropin levels in patients diagnosed with SLE.
- To explore the association between adropin levels and coronary risk factors in SLE.
- To examine the relationship between adropin and clinical manifestations of SLE.
Main Methods:
- A cross-sectional study involving 59 SLE patients and 30 healthy controls.
- Serum adropin levels were quantified using high-sensitivity human ELISA kits.
Main Results:
- SLE patients exhibited significantly lower serum adropin levels compared to controls (0.41 vs. 0.69 ng/mL, p=0.001).
- Lower adropin levels were associated with hyperlipidemia, hypertension, nephritis, serositis, hypocomplementemia, and positive anti-phospholipid antibodies (APLAs).
- Serum adropin levels negatively correlated with disease duration and were independently associated with hypertension and APLAs.
Conclusions:
- Serum adropin levels are significantly decreased in SLE patients.
- Adropin may serve as a potential biomarker for cardiovascular risk, particularly hypertension, in SLE.
- These findings highlight adropin's clinical relevance in assessing cardiovascular risk within the SLE population.
More Related Videos
Related Concept Videos
01:26Atherosclerosis III: Management
529
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
529
01:24Nephrotic Syndrome I : Introduction
784
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
784
01:30Peripheral Artery Disease I: Introduction
497
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
497